

Policy Category:

**INNF**

Who usually applies for funding?

**Consultant**



## High cost, non- NICE approved, Tariff excluded medicines.

**Commissioning decision**

**High cost, non- NICE approved Tariff excluded medicines are considered a low priority for funding and will only be considered in exceptional circumstances.**

### Policy Statement:

The Tariff Excluded drugs that are routinely commissioned by Gloucestershire ICB are categorised as follows:

- Category 1 – These are drugs that have been recommended by NICE as part of a Technology Appraisal Guidance (NICE TA). Drugs listed in this category must only be used as per NICE criteria.
- Category 2 – Drugs that are not covered by a NICE TA but are funded by a commissioning agreement with the ICB.

Drugs that do not appear in either of the above categories will not be routinely funded by the ICB and prior approval must be sought from the ICBs via the Individual Funding Request (IFR).

This policy only covers Tariff Excluded drugs as defined by the Department of Health (DH).

The ICB will not commission or pay for drugs/devices for which NHS England is the responsible commissioner.

### Rationale:

NHS National Tariff is the payment system in England under which commissioners pay healthcare providers for each patient seen or treated, taking into account the complexity of the patient's healthcare needs.

The two fundamental features of NHS National Tariff are nationally determined currencies and tariffs. NHS National Tariff currently covers the majority of acute healthcare in hospitals, with national tariffs for admitted patient care, outpatient attendances, accident and emergency (A&E), and some outpatient procedures.

The National Institute for Health and Care Excellence (NICE) provides national guidance, advice, quality standards and information services to improve health, public health and social care. Contains resources to help maximise use of evidence and guidance.

NICE guidance documents are evidence-based recommendations developed by independent committees, including professionals and lay members, and consulted on by stakeholders. New treatments are reviewed for their clinical and cost effectiveness and if approved by means of a Technology Appraisal it is mandatory for that treatment to be available within 90 days of the publication (or 30 days in the event of a rapid review).

Therefore, where a Tariff excluded medicine is desired by a prescriber exceptionality will need to be demonstrated and an application via IFR route will be required for funding to be considered.

**Policy Category:****INNF****Who usually applies for funding?****Consultant****Evidence base:**NICE website <https://www.nice.org.uk/>[High Cost Drugs exc from tariff \(elmbb.nhs.uk\)](http://elmbb.nhs.uk)

Other ICB policies e.g. 2020-21 South West London (SWL)

[South West London Interface Prescribing Policy \(icb.nhs.uk\)](http://icb.nhs.uk)For further information please contact [GLICB.IFR@nhs.net](mailto:GLICB.IFR@nhs.net)

<b>Date of publication</b>	
<b>Policy review date</b>	December 2026

**Policy sign off**

<b>Reviewing Body</b>	<b>Date of review</b>
Effective Clinical Commissioning Policy Group	10.12.2020
Quality and Governance Committee	

**Version Control**

<b>Version No</b>	<b>Type of Change</b>	<b>Date</b>	<b>Description of Change</b>
0.1	Policy statement clarified	Oct 2020	Full policy template completed. Review date set at Dec 2023 by ECCP Group.
0.2	Review date Title change	Dec 2023	Review date changed to December 2026 Title amended from Payment by Results (PBR) to Tariff.